undamentalytics Newsletter
Sign in

Aytu Biopharma, Inc (AYTU) stock

Add to watchlist

Add holding +

NASDAQ: AYTU Nasdaq Pharmaceuticals Next results ~December 17, 2026

C Fundamentals grade

Aytu Biopharma, Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$8.2

Revenue-to-maturity cash-flow model

Base case. Range ~$8.2–$10 across our lower- and higher-growth cases (0%–5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Aytu Biopharma, Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds14 adding, 7 cuttingOf 4 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Aytu Biopharma files

Where Aytu Biopharma stands after its latest 10-K

Revenue for the twelve months to June 2026 was $58m, down 13.3% on a year earlier, a smaller fall than the 14.0% decline a quarter earlier. That puts it 43 of 47 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin rose to 5.6% from -3.3% a year earlier. Operating margin narrowed to -14.4% from -11.8%. The diluted share count is up 52.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 4 of our 6 financial-health checks. Our revenue-to-maturity cash-flow model value is $8.10 a share, against a share price of $1.97.

Source: 10-K filed September 22, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~December 17, 2026 (estimated)

Aytu Biopharma, Inc's trailing-twelve-month revenue fell 13.3% year on year, with a free-cash-flow margin of 5.6%. Where it lags: change in share count of 52.9% ranks 59 of 62 pharmaceuticals companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 83% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Revenue shrinking. Revenue fell 13.3% over the last 12 months.
  • Loss-making. Operating margin is -14.4%: costs exceed revenue.
  • Share dilution. Diluted shares rose 52.9% in a year.
  • Gross margin slipping. Gross margin is down 5.1 points on a year ago.
  • Below peers: days sales outstanding. Days sales outstanding of 144 days ranks 49 of 59 pharmaceuticals companies we cover (median 72 days).

Latest results: FY2026 Q4

Filed September 22, 2026
Earnings per share
-$0.06 against an average estimate of -$0.35: beat by 82.7%
Revenue
$16m, up 6.4% on a year earlier
Share reaction
+7.0% in the first session after the results on September 22, 2026, against -0.7% for the S&P 500

Aytu Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.5%
  • 1 week+0.5%
  • 1 month-6.3%
  • This year-25.4%
  • 1 year-14.5%
  • 5 years-96.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$57.6M
Operating margin
-14.4%
Net margin
-24.8%
EPS (TTM, diluted)
$-1.16

Growth

Revenue growth
−13.3%
Change in growth rate
+0.8 pts
Share count change
+52.9%

Cash

Free cash flow (TTM)
$3.3M
FCF margin
5.6%
Stock pay % of revenue
1.2%

Earnings

Last results
September 22, 2026
Next results (est.)
December 17, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aytu Biopharma, Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Aytu Biopharma, Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.88 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$8.2 ~$8.2–$10 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$5.6–$24 Left out: out of range vs price (0.01x)
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$8.2 ~$8.2–$10 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aytu Biopharma, Inc with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026
Share price$374400.00$47200.00$1040.00$378.00$284.00$100.20$13.80$1.60$2.92$2.18$2.15
Market value$3.26tn$2.2bn$69.2bn$295m$128m$168m$41m$11m$32m$27m$26m
+ Net debt (− = net cash)−$7m−$802328−$7m−$11m−$33m−$25m−$547000−$6m−$5m−$9m−$9m
Enterprise value$3.26tn$2.2bn$69.2bn$284m$95m$143m$40m$4m$27m$18m$17m
Multiples
Price / sales n/mn/mn/m40.2x4.6x2.6x0.4x0.1x0.5x0.4x0.5x
Price / earnings ———————————
Price / free cash flow ——————————8.1x
EV / EBITDA ————————4.1x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Aytu Biopharma's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -17.8% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 63.0%, moving by 10.0 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -83.1%; its worst year was -624.7%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 6 years, at a median -116.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.36 +56% $68m +18%
Next $0.15 +143% $87m +28%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +386.7% on 90 days ago. In the last 30 days, 0 analysts raised Aytu Biopharma, Inc's forecast and 2 cut it.

Consensus EPS forecast Aytu Biopharma, Inc, last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.07 Current fiscal year, 60 days ago: −$0.07 Current fiscal year, 30 days ago: −$0.07 Current fiscal year, 7 days ago: −$0.07 Current fiscal year, Now: −$0.36 −$0.36

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$0.07
60 days ago −$0.07
30 days ago −$0.07
7 days ago −$0.07
Now −$0.36

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.35 −$0.06 +82.7%
Mar 2026 −$0.42 −$0.41 +2.4%
Dec 2025 −$0.49 −$0.23 +52.9%
Sept 2025 −$0.20 −$0.09 +52.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, September 22, 2026

No numeric guidance in Aytu Biopharma, Inc's latest earnings release (filed September 22, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026123
  3. Aug 2026123

Counts of recommendations published by analysts covering Aytu Biopharma, Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.5%
of tradable shares
Days to cover
6.8
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
36%
of shares
Held by insiders
8.2%
of shares
Employees
75
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AYTU−77%−86%−25%−40%+53%−25%
Industry peers (median)−18%−49%−13%−2%+7%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AYTU17%17%42%33%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AYTU−86%−90%−66%−60%−47%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 2, 2015 to April 7, 2025. Getting back needed a 431999900% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.90 – $2.90
From 52-week high
−33.1%
vs 50-day average
−7.4%
vs 200-day average
−16.1%
Volatility (1 year)
44%
Beta vs S&P 500
0.78

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±14.2%
After a week
2 up, 10 down
typical move ±11.5%
After a month
2 up, 10 down
typical move ±12.9%
Results releasedNext dayS&P 500 next day5 days21 days
September 22, 2026 +7.0% −0.7% +3.3% −8.0%
May 13, 2026 −1.3% +1.4% −6.5% −6.5%
April 2, 2026 +0.8% +0.6% −3.4% −3.4%
February 3, 2026 −13.3% −1.3% −14.8% −4.4%
November 13, 2025 +1.5% −1.7% −5.8% +13.1%
September 23, 2025 −17.3% −0.9% −24.5% −8.8%
May 14, 2025 +97.7% +0.6% +54.2% +48.9%
February 12, 2025 −2.8% +0.7% −2.8% −15.5%
November 13, 2024 −10.9% −0.6% −14.4% −17.2%
September 26, 2024 −2.9% +0.3% −1.2% −11.1%
May 15, 2024 −10.8% +1.0% −6.0% −14.2%
February 14, 2024 +4.3% +1.6% −1.0% −4.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Aytu Biopharma, Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Aytu Biopharma, Inc
$40M $60M $80M $100M FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue (TTM), FY24 Q1: $97.6M Revenue (TTM), FY24 Q2: $90M Revenue (TTM), FY24 Q3: $81.3M Revenue (TTM), FY24 Q4: $65.2M Revenue (TTM), FY25 Q1: $63.9M Revenue (TTM), FY25 Q2: $61.4M Revenue (TTM), FY25 Q3: $65.8M Revenue (TTM), FY25 Q4: $66.4M Revenue (TTM), FY26 Q1: $63.7M Revenue (TTM), FY26 Q2: $62.6M Revenue (TTM), FY26 Q3: $56.6M Revenue (TTM), FY26 Q4: $57.6M $57.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $97.6M
FY24 Q2 $90M
FY24 Q3 $81.3M
FY24 Q4 $65.2M
FY25 Q1 $63.9M
FY25 Q2 $61.4M
FY25 Q3 $65.8M
FY25 Q4 $66.4M
FY26 Q1 $63.7M
FY26 Q2 $62.6M
FY26 Q3 $56.6M
FY26 Q4 $57.6M
Revenue growth, TTM YoY Aytu Biopharma, Inc
-40% -20% 0% 20% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue growth, TTM YoY, FY24 Q1: -4.8% Revenue growth, TTM YoY, FY24 Q2: -14.7% Revenue growth, TTM YoY, FY24 Q3: -21.9% Revenue growth, TTM YoY, FY24 Q4: -39.3% Revenue growth, TTM YoY, FY25 Q1: -34.5% Revenue growth, TTM YoY, FY25 Q2: -31.8% Revenue growth, TTM YoY, FY25 Q3: -19.0% Revenue growth, TTM YoY, FY25 Q4: 1.8% Revenue growth, TTM YoY, FY26 Q1: -0.4% Revenue growth, TTM YoY, FY26 Q2: 2.0% Revenue growth, TTM YoY, FY26 Q3: -14.0% Revenue growth, TTM YoY, FY26 Q4: -13.3% -13.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 -4.8%
FY24 Q2 -14.7%
FY24 Q3 -21.9%
FY24 Q4 -39.3%
FY25 Q1 -34.5%
FY25 Q2 -31.8%
FY25 Q3 -19.0%
FY25 Q4 1.8%
FY26 Q1 -0.4%
FY26 Q2 2.0%
FY26 Q3 -14.0%
FY26 Q4 -13.3%
Operating margin (TTM) Aytu Biopharma, Inc
-30% -20% -10% 0% 10% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Operating margin (TTM), FY24 Q1: -16.5% Operating margin (TTM), FY24 Q2: -6.8% Operating margin (TTM), FY24 Q3: 1.0% Operating margin (TTM), FY24 Q4: -2.4% Operating margin (TTM), FY25 Q1: -2.6% Operating margin (TTM), FY25 Q2: -10.6% Operating margin (TTM), FY25 Q3: -3.8% Operating margin (TTM), FY25 Q4: -11.8% Operating margin (TTM), FY26 Q1: -13.2% Operating margin (TTM), FY26 Q2: -13.9% Operating margin (TTM), FY26 Q3: -26.8% Operating margin (TTM), FY26 Q4: -14.4% -14.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 -16.5%
FY24 Q2 -6.8%
FY24 Q3 1.0%
FY24 Q4 -2.4%
FY25 Q1 -2.6%
FY25 Q2 -10.6%
FY25 Q3 -3.8%
FY25 Q4 -11.8%
FY26 Q1 -13.2%
FY26 Q2 -13.9%
FY26 Q3 -26.8%
FY26 Q4 -14.4%
FCF margin (TTM) Aytu Biopharma, Inc
-300% -200% -100% 0% 100% FY19 Q4 FY20 Q3 FY25 Q3 FY26 Q4 FCF margin (TTM), FY19 Q4: -189.8% FCF margin (TTM), FY20 Q1: -192.8% FCF margin (TTM), FY20 Q2: -234.5% FCF margin (TTM), FY20 Q3: 15.1% FCF margin (TTM), FY20 Q4: 13.6% FCF margin (TTM), FY25 Q2: 0.3% FCF margin (TTM), FY25 Q3: -9.2% FCF margin (TTM), FY25 Q4: -3.3% FCF margin (TTM), FY26 Q1: -2.3% FCF margin (TTM), FY26 Q2: -1.1% FCF margin (TTM), FY26 Q3: 2.9% FCF margin (TTM), FY26 Q4: 5.6% 5.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY19 Q4 -189.8%
FY20 Q1 -192.8%
FY20 Q2 -234.5%
FY20 Q3 15.1%
FY20 Q4 13.6%
FY25 Q2 0.3%
FY25 Q3 -9.2%
FY25 Q4 -3.3%
FY26 Q1 -2.3%
FY26 Q2 -1.1%
FY26 Q3 2.9%
FY26 Q4 5.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 0 0 3 3 4 7 28 66 97 107 65 66 58
Gross profit — 0 2 2 2 5 19 29 52 67 49 46 37
EBITDA −6 −8 −21 −16 −17 −14 −15 −50 −100 −8 7 −2 −4
Operating income −6 −8 −22 −20 −20 −17 −21 −59 −110 −17 −2 −8 −8
Net income −6 −8 −28 −23 −10 −27 −14 −58 −109 −17 −16 −14 −14
Diluted EPS −$1920.00 −$2014.00 −$3237.00 −$483.00 −$153.10 −$34.80 −$30.10 −$34.80 −$37.01 −$2.56 — — —
Growth (year on year)
Revenue — +344.2% +878.8% +25.7% +13.6% +100.0% +277.5% +137.5% +47.3% +11.1% −39.3% +1.8% −13.3%
EBITDA — — — — — — — — — — — −136.7% —
Margins
Gross margin — 66.3% 62.6% 56.0% 44.0% 69.9% 70.0% 44.5% 54.1% 62.0% 75.3% 69.0% 64.0%
EBITDA margin <−999% <−999% −812.9% −489.2% −467.4% −192.9% −55.8% −75.7% −103.2% −7.7% 10.2% −3.7% −7.6%
Operating margin <−999% <−999% −847.0% −624.7% −538.2% −230.1% −76.5% −89.7% −113.7% −15.9% −2.4% −11.8% −14.4%
Net margin <−999% <−999% <−999% −698.7% −278.3% −370.6% −49.3% −88.8% −112.5% −15.9% −24.3% −20.4% −24.8%
Free-cash-flow margin <−999% <−999% −425.8% −432.7% −437.6% −189.8% −102.7% −43.1% −29.8% — −2.6% −3.3% 5.6%
Cash flow
Cash from operations −6 −7 −11 −14 −16 −14 −28 −26 −29 −5 −1 −2 3
Capital spending 0 0 0 0 0 0 0 2 0 — 0 0 0
Free cash flow −6 −7 −11 −14 −16 −14 −28 −28 −29 — −2 −2 3
Stock-based pay 0 1 1 3 1 1 1 4 5 6 2 1 1
Free cash flow after stock pay −6 −8 −12 −16 −17 −15 −29 −32 −34 — −4 −3 3
Balance sheet
Cash 3 7 8 1 7 11 48 50 19 23 20 31 26
Total debt 0 0 1 0 0 0 15 25 19 17 15 22 17
Net debt (negative = net cash) −3 −7 −7 −1 −7 −11 −33 −25 −1 −6 −5 −9 −9
Diluted shares — — 9m — 67m — — 2m 3m 7m 11m 13m 12m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $105m
Short-term assets $62mLonger-term assets $43m
What it owes, and who funded it · $90m
Short-term liabilities $55mShareholders' equity $35m
  • Short-term assets cover short-term liabilities $62m of assets due within a year against $55m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $26m of cash against $11m of debt.
  • Debt below 40% of shareholders' equity Debt is 31% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 31% over five years.
  • A year's operating cash flow covers at least 20% of debt $3m of operating cash flow against $11m of debt.
  • Operating profit covers interest at least five times over Operating income of −$8m against $2m of interest.

From Aytu Biopharma, Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+52.9%
year over year
R&D spending
0.0%
of revenue
Days sales outstanding
144 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated AYTU AQST DERM RMTI BFRI CPIX Median
Revenue, last 12 months $58m $54m $68m $69m $46m $40m $276m
Revenue growth, last 12 months −13.3% 22.6% 20.9% −21.1% 17.8% −5.2% 9.9%
Revenue growth, 3-year average −18.8% 5.2% 3.5% −2.9% 16.7% −0.6% 5.5%
Revenue growth, latest quarter 6.4% 38.1% 23.3% 10.6% 32.9% −18.8% 6.5%
Gross margin 64.0% 67.0% 69.4% 17.7% — 82.9% 62.0%
Operating margin −14.4% −97.5% −4.4% −6.5% −14.2% −24.1% −5.9%
Operating margin, 3-year average −9.6% −80.9% −4.6% −3.8% −36.6% −19.0% −7.4%
Net margin −24.8% −144.6% −9.0% −7.3% −13.8% −27.4% −7.3%
Cash from operations / revenue 5.7% −83.9% −11.0% 4.2% −17.2% 1.9% 10.2%
Free-cash-flow margin 5.6% −85.0% 0.3% 2.2% −17.2% 1.7% 8.6%
Free-cash-flow margin, 3-year average 5.8% −80.3% — — −31.6% 5.4% 7.4%
Stock pay / revenue 1.2% 17.3% 8.9% 2.7% 2.4% 1.1% 3.6%
Change in share count 52.9% 27.4% 21.6% 9.9% — 1.5% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -13.3% 10.0% 62 of 74
Change in growth rate Growth +0.8pp -0.3pp 34 of 74
Gross margin Profitability 64.0% 59.8% 27 of 59
Operating margin Profitability -14.4% -5.9% 39 of 67
Net margin Profitability -24.8% -7.3% 53 of 75
Free-cash-flow margin Cash generation 5.6% 10.1% 40 of 74
Stock pay as % of revenue Cash generation 1.2% 3.6% 17 of 69
Long-term debt as % of assets Balance sheet 8.7% 23.8% 14 of 53
Change in share count Balance sheet 52.9% 1.5% 59 of 62
Days sales outstanding Balance sheet 144 days 72 days 49 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$10.6M
Institutions reporting
36
Shares held vs prior quarter
▲ 26.1%
Positions opened / closed
4 / 2

Top buyers and sellers, Q2 2026: 14 institutions bought and 7 sold ; the biggest buyer was Nantahala Capital Management, LLC (+1.1M shares) and the biggest seller Diadema Partners LP (−205K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $4.7M 2.2M 44.2% ▲ 100.0%
Stonepine Capital Management, LLC $2M 913K 18.5% ▲ 15.2%
Awm Investment Company, Inc. $1.3M 620K 12.6% 0.0%
Vanguard Capital Management LLC $561,464 261K 5.3% 0.0%
Crown Advisors Management, Inc. $430,000 200K 4.1% ▲ 37.9%
Diadema Partners LP $319,374 149K 3.0% ▼ 57.9%
Two Sigma Investments, LP $226,451 105K 2.1% ▼ 13.6%
Renaissance Technologies LLC $225,369 105K 2.1% ▲ 11.8%
Geode Capital Management, LLC $201,371 94K 1.9% ▲ 1.1%
Citadel Advisors LLC $106,240 49K 1.0% ▲ 34.1%
Vanguard Fiduciary Trust Co $101,153 47K 1.0% 0.0%
Dimensional Fund Advisors LP $97,451 45K 0.9% ▲ 4.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aytu Biopharma, Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around December 17, 2026 estimated from the company's past filing pattern, not announced

  • September 22, 2026
  • May 13, 2026
  • April 2, 2026
  • February 3, 2026
  • November 13, 2025
  • September 23, 2025

Recent SEC filings

Data status

When each part of this page on Aytu Biopharma, Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aytu Biopharma, Inc in brief

What does Aytu Biopharma, Inc do?
Aytu Biopharma, Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
What is Aytu Biopharma, Inc's stock ticker?
Aytu Biopharma, Inc trades under the ticker AYTU on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Aytu Biopharma, Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Aytu Biopharma, Inc reported revenue of $57.6M, 13.3% lower than a year earlier, according to its SEC filings.
What is Aytu Biopharma, Inc's free cash flow?
Aytu Biopharma, Inc's free-cash-flow margin is 5.6% of revenue over the trailing twelve months, ranking 40 of the 74 pharmaceuticals companies we cover.
Who are Aytu Biopharma, Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Stonepine Capital Management, LLC and Awm Investment Company, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Aytu Biopharma, Inc's market cap?
On June 30, 2026, Aytu Biopharma, Inc's market capitalisation was about $26.5M and net debt of -$9.3M. Market figures come from third-party market data and may be delayed.
How much debt does Aytu Biopharma, Inc have?
Aytu Biopharma, Inc's debt-to-equity ratio is 31.1%, from its latest balance sheet (0.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Aytu Biopharma, Inc's competitors?
In our Pharmaceuticals peer group, the companies closest to Aytu Biopharma, Inc are Aquestive Therapeutics, Inc., Journey Medical Corp, Rockwell Medical, Inc., Biofrontera Inc. and Cumberland Pharmaceuticals Inc. The side-by-side comparison below sets their revenue, margins and growth against Aytu Biopharma, Inc's.
When is Aytu Biopharma, Inc's next earnings date?
Around December 17, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aytu Biopharma, Inc announces its own schedule.